Reason for request
Re-assessment of the actual benefit at the request of the Transparency
Clinical Benefit
| Low |
Le service médical rendu par MEGACE 160 mg est faible dans le traitement palliatif des carcinomes du sein.
|
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
PjYCkuksvvEFJdTv
